Announcements Trials

Browse Landscape

Phase

Phase 2 3 Phase NA 1 Phase 3 1 Phase 2/3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma 76 Gastrointestinal Stromal Tumors 36 Dendritic Cell Sarcoma, Interdigitating 22 Glioblastoma 20 Liposarcoma 19 Gliosarcoma 19 Neoplasms 18 Leiomyosarcoma 16 Bone Neoplasms 16 Rhabdomyosarcoma 15 Neoplasm Metastasis 15 Lymphoma, Large B-Cell, Diffuse 15 Burkitt Lymphoma 15 Central Nervous System Neoplasms 14 Sarcoma, Synovial 13 Recurrence 13 Precursor Cell Lymphoblastic Leukemia-Lymphoma 13 Osteosarcoma 13 Hemangiosarcoma 12 Fibrosarcoma 12 Multiple Myeloma 11 Lymphoma, Non-Hodgkin 11 Lymphoma, Mantle-Cell 11 Lymphoma, Large-Cell, Immunoblastic 11 Lymphoma, Follicular 11 Lymphoma, B-Cell, Marginal Zone 11 Lymphoma 11 Leukemia, Myeloid, Chronic-Phase 11 Leukemia, Myeloid, Acute 11 Leukemia, Myeloid, Accelerated Phase 11

Interventions

olverembatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × GIST × Sarcoma × Clear all

NCT06640361 2024-12-27

A Study of Olverembatinib in SDH-deficient GIST.

Ascentage Pharma Group Inc.

Phase 3 Recruiting

GIST

Data powered by HemOnc (CC BY 4.0) Colophon ⚡